By / April 21, 2023

France Is Out of Stock… Again

After France faced a shortage of the most-prescribed product in its medical cannabis trial program that’s currently ongoing, the health authorities recommended falling back on a CBD:THC 20:1 oil. Unluckily – or unanticipated – the 20:1 ratio oil was announced to be out of stock on Wednesday morning, April 19.

Does this sound like the end of the medical cannabis experiment in France? In any case, the signal sent is very worrying, but nothing is certain yet. So to keep up with this story, download our free cannabis news app.

France Faces a “Transitional Situation”

“We are in a transitional situation where we have no more products,” said Professor Authier to the French journal Le Quotidien du Médecin. “It is a very negative signal: France will have difficulty keeping health professionals in the experimentation,” he predicts.

Having run out of CBD 50 oil supplied by the Australian Little Green Pharma (LGP), the professor had been able to fall back on 20:1 oil, also supplied by LGP, for some patients in France with resistant neuropathic pain.

“And now I’m going to be stuck, because I’ll just have to offer them a balanced ratio of THC and CBD. He says. I also have patients who can’t tolerate THC, and I have nothing left to offer them.”

A Symposium Seeks Solutions

A briefing was held this Friday, April 21, at the DGS on the issue of the status of therapeutic cannabis in France, its possible reimbursement, and its possible legalization. As he had described during a recent symposium at the National Assembly in France, decisions must be taken quickly to not miss the boat of generalization.

“We need to make decisions before the summer,” said Professor Authier. “Otherwise, it will be too late to bring cannabis into the common law in France.”

Why Is France Out of Stock Again?

As for a reason for the out-of-stock, the role of the Directorate General of Health (DGS) in France is still pointed to.

“The calls for tender were launched too late,” says Professor Authier. “We go from administrative error to administrative error,” he laments.

Little Green Pharma, which supplies the two products that are out of stock in France, did not want to renew its contract for another year, as the first two years cost it around 10 million euros, according to our information.

The DGS is now trying to limit the costs after having failed to allocate all the lots of a first call for tenders aiming at providing the extension of the first two years of the experimentation in France. A second tender is currently underway to replace the supplier and/or the CBD 50 oil that failed in the first place. Is all of this just a warmup for a third tender for the 20:1 oil in France?

(Featured image by WeStarMoney via Pexels)

DISCLAIMER: This article was written by a third-party contributor and does not reflect the opinion of, its management, staff, or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the company may believe that its expectations are based on reasonable assumptions, the actual results that the company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in Newsweed, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

Comments are closed for this post.